Human cytomegalovirus (HCMV) is an important pathogen that infects the majority of the population worldwide, yet, currently, there is no licensed vaccine. Despite HCMV encoding at least seven Natural Killer (NK) cell evasion genes, NK cells remain critical for the control of infection in vivo. Classically Antibody-Dependent Cellular Cytotoxicity (ADCC) is mediated by CD16, which is found on the surface of the NK cell in a complex with FcεRI-γ chains and/or CD3ζ chains. Ninety percent of NK cells express the Fc receptor CD16; thus, they have the potential to initiate ADCC. HCMV has a profound effect on the NK cell repertoire, such that up to 10-fold expansions of NKG2C + cells can be seen in HCMV seropositive individuals. These NKG2C + cells are reported to be FcεRI-γ deficient and possess variable levels of CD16 +, yet have striking ADCC functions. A subset of HCMV cell surface proteins will induce robust antibody responses that could render cells susceptible to ADCC. We will consider how the strong anti-HCMV function of NKG2C + FcεRI-γ-deficient NK cells could potentially be harnessed in the clinic to treat patients suffering from HCMV disease and in the development of an efficacious HCMV vaccine.
References
[1]
Patel, R.; Snydman, D.R.; Rubin, R.H.; Ho, M.; Pescovitz, M.; Martin, M.; Paya, C.V. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996, 61, 1279–1289, doi:10.1097/00007890-199605150-00001.
[2]
Mocarski, E.S.; Thomas, S.T.; Griffiths, P.; Pass, R.F. Cytomegaloviruses in Fields Virology; Knipe, D.M., Howley, P., Eds.; Lippincott Williams and Wilkins: Philadelphia, PA, USA, 2013; Volume 2.
[3]
Baldanti, F.; Lurain, N.; Gerna, G. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum. Immunol. 2004, 65, 403–409, doi:10.1016/j.humimm.2004.02.007.
[4]
Dollard, S.C.; Grosse, S.D.; Ross, D.S. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev. Med. Virol. 2007, 17, 355–363, doi:10.1002/rmv.544.
[5]
Stratton, K.R.; Durch, J.S.; Lawrence, R.S. Vaccines for the 21st Century; National Academies Press: Washington, DC, USA, 2000.
[6]
Avetisyan, G.; Aschan, J.; Hagglund, H.; Ringden, O.; Ljungman, P. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant. 2007, 40, 865–869, doi:10.1038/sj.bmt.1705825.
[7]
Barron, M.A.; Gao, D.; Springer, K.L.; Patterson, J.A.; Brunvand, M.W.; McSweeney, P.A.; Zeng, C.; Baron, A.E.; Weinberg, A. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 2009, 49, 1777–1783, doi:10.1086/648423.
[8]
Cwynarski, K.; Ainsworth, J.; Cobbold, M.; Wagner, S.; Mahendra, P.; Apperley, J.; Goldman, J.; Craddock, C.; Moss, P.A. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001, 97, 1232–1240, doi:10.1182/blood.V97.5.1232.
[9]
Tormo, N.; Solano, C.; Benet, I.; Clari, M.A.; Nieto, J.; de la Camara, R.; Lopez, J.; Lopez-Aldeguer, N.; Hernandez-Boluda, J.C.; Remigia, M.J.; et al. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2010, 45, 543–549, doi:10.1038/bmt.2009.172.
[10]
Sylwester, A.W.; Mitchell, B.L.; Edgar, J.B.; Taormina, C.; Pelte, C.; Ruchti, F.; Sleath, P.R.; Grabstein, K.H.; Hosken, N.A.; Kern, F.; et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 2005, 202, 673–685, doi:10.1084/jem.20050882.
[11]
Einsele, H.; Roosnek, E.; Rufer, N.; Sinzger, C.; Riegler, S.; Loffler, J.; Grigoleit, U.; Moris, A.; Rammensee, H.G.; Kanz, L.; et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002, 99, 3916–3922, doi:10.1182/blood.V99.11.3916.
[12]
Peggs, K.S.; Verfuerth, S.; Pizzey, A.; Khan, N.; Guiver, M.; Moss, P.A.; Mackinnon, S. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003, 362, 1375–1377, doi:10.1016/S0140-6736(03)14634-X.
[13]
Riddell, S.R.; Watanabe, K.S.; Goodrich, J.M.; Li, C.R.; Agha, M.E.; Greenberg, P.D. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992, 257, 238–241.
[14]
Walter, E.A.; Greenberg, P.D.; Gilbert, M.J.; Finch, R.J.; Watanabe, K.S.; Thomas, E.D.; Riddell, S.R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 1995, 333, 1038–1044, doi:10.1056/NEJM199510193331603.
[15]
Biron, C.A.; Byron, K.S.; Sullivan, J.L. Severe Herpesvirus Infections in an Adolescent without Natural-Killer Cells. N. Engl. J. Med. 1989, 320, 1731–1735, doi:10.1056/NEJM198906293202605.
Orange, J.S.; Brodeur, S.R.; Jain, A.; Bonilla, F.A.; Schneider, L.C.; Kretschmer, R.; Nurko, S.; Koehler, J.R.; Rasmussen, W.L.; Fergusson, B.M.; et al. Deficiency of natural cytotoxicity in patients with IKK gamma/NEMO mutations. Faseb J. 2002, 16, A1242–A1242, doi:10.1096/fj.02-0127hyp.
[18]
Cunningham-Rundles, C. Human B cell defects in perspective. Immunol. Res. 2012, 54, 227–232, doi:10.1007/s12026-012-8318-2.
[19]
Aspalter, R.M.; Sewell, W.A.C.; Dolman, K.; Farrant, J.; Webster, A.D.B. Deficiency in circulating natural killer (NK) cell subsets in common variable immunodeficiency and X-linked agammaglobulinaemia. Clin. Exp. Immunol. 2000, 121, 506–514.
[20]
Witte, T.; Werwitzke, S.; Schmidt, R.E. CMV complications in common variable immunodeficiency. Immunobiology 2000, 202, 194–198, doi:10.1016/S0171-2985(00)80066-2.
[21]
Rai, N.; Thakur, N. Congenital CMV With LAD Type 1 and NK Cell Deficiency. J. Pediatr. Hematol. Oncol. 2013, 35, 468–469, doi:10.1097/MPH.0b013e31827e57b2.
[22]
Long, E.O.; Kim, H.S.; Liu, D.; Peterson, M.E.; Rajagopalan, S. Controlling natural killer cell responses: Integration of signals for activation and inhibition. Annu. Rev. Immunol. 2013, 31, 227–258, doi:10.1146/annurev-immunol-020711-075005.
[23]
Guma, M.; Angulo, A.; Vilches, C.; Gomez-Lozano, N.; Malats, N.; Lopez-Botet, M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 2004, 104, 3664–3671, doi:10.1182/blood-2004-05-2058.
[24]
Orange, J.S.; Brodeur, S.R.; Jain, A.; Bonilla, F.A.; Schneider, L.C.; Kretschmer, R.; Nurko, S.; Rasmussen, W.L.; Kohler, J.R.; Gellis, S.E.; et al. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J. Clin. Invest. 2002, 109, 1501–1509.
[25]
Gazit, R.; Garty, B.Z.; Monselise, Y.; Hoffer, V.; Finkelstein, Y.; Markel, G.; Katz, G.; Hanna, J.; Achdout, H.; Gruda, R.; et al. Expression of KIR2DL1 on the entire NK cell population: a possible novel immunodeficiency syndrome. Blood 2004, 103, 1965–1966, doi:10.1182/blood-2003-11-3796.
[26]
Kuijpers, T.W.; Baars, P.A.; Dantin, C.; van den Burg, M.; van Lier, R.A.; Roosnek, E. Human NK cells can control CMV infection in the absence of T cells. Blood 2008, 112, 914–915, doi:10.1182/blood-2008-05-157354.
[27]
Prod’homme, V.; Griffin, C.; Aicheler, R.J.; Wang, E.C.; McSharry, B.P.; Rickards, C.R.; Stanton, R.J.; Borysiewicz, L.K.; Lopez-Botet, M.; Wilkinson, G.W.; et al. The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1- NK cells. J. Immunol. 2007, 178, 4473–4481.
[28]
Cosman, D.; Fanger, N.; Borges, L.; Kubin, M.; Chin, W.; Peterson, L.; Hsu, M.L. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunobiology 1997, 7, 273–282.
[29]
Tomasec, P.; Braud, V.M.; Rickards, C.; Powell, M.B.; McSharry, B.P.; Gadola, S.; Cerundolo, V.; Borysiewicz, L.K.; McMichael, A.J.; Wilkinson, G.W. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000, 287, 1031, doi:10.1126/science.287.5455.1031.
[30]
Wang, E.C.; McSharry, B.; Retiere, C.; Tomasec, P.; Williams, S.; Borysiewicz, L.K.; Braud, V.M.; Wilkinson, G.W. UL40-mediated NK evasion during productive infection with human cytomegalovirus. Proc. Natl. Acad. Sci. USA 2002, 99, 7570–7575, doi:10.1073/pnas.112680099.
[31]
Ulbrecht, M.; Martinozzi, S.; Grzeschik, M.; Hengel, H.; Ellwart, J.W.; Pla, M.; Weiss, E.H. Cutting edge: The human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J. Immunol. 2000, 164, 5019–5022.
[32]
Arnon, T.I.; Achdout, H.; Levi, O.; Markel, G.; Saleh, N.; Katz, G.; Gazit, R.; Gonen-Gross, T.; Hanna, J.; Nahari, E.; et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat. Immunol. 2005, 6, 515–523.
[33]
Welte, S.A.; Sinzger, C.; Lutz, S.Z.; Singh-Jasuja, H.; Sampaio, K.L.; Eknigk, U.; Rammensee, H.G.; Steinle, A. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur. J. Immunol. 2003, 33, 194–203, doi:10.1002/immu.200390022.
[34]
Wu, J.; Chalupny, N.J.; Manley, T.J.; Riddell, S.R.; Cosman, D.; Spies, T. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. J. Immunol. 2003, 170, 4196–4200.
[35]
Dunn, C.; Chalupny, N.J.; Sutherland, C.L.; Dosch, S.; Sivakumar, P.V.; Johnson, D.C.; Cosman, D. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J. Exp. Med. 2003, 197, 1427–1439, doi:10.1084/jem.20022059.
[36]
Rolle, A.; Mousavi-Jazi, M.; Eriksson, M.; Odeberg, J.; Soderberg-Naucler, C.; Cosman, D.; Karre, K.; Cerboni, C. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. J. Immunol. 2003, 171, 902–908.
[37]
Vales-Gomez, M.; Browne, H.; Reyburn, H.T. Expression of the UL16 glycoprotein of Human Cytomegalovirus protects the virus-infected cell from attack by natural killer cells. BMC Immunol. 2003, 4, 4, doi:10.1186/1471-2172-4-4.
[38]
Kubin, M.; Cassiano, L.; Chalupny, J.; Chin, W.; Cosman, D.; Fanslow, W.; Mullberg, J.; Rousseau, A.M.; Ulrich, D.; Armitage, R. ULBP1, 2, 3: Novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. Eur. J. Immunol. 2001, 31, 1428–1437, doi:10.1002/1521-4141(200105)31:5<1428::AID-IMMU1428>3.0.CO;2-4.
[39]
Spreu, J.; Stehle, T.; Steinle, A. Human cytomegalovirus-encoded UL16 discriminates MIC molecules by their alpha2 domains. J. Immunol. 2006, 177, 3143–3149.
[40]
Stern-Ginossar, N.; Elefant, N.; Zimmermann, A.; Wolf, D.G.; Saleh, N.; Biton, M.; Horwitz, E.; Prokocimer, Z.; Prichard, M.; Hahn, G.; et al. Host immune system gene targeting by a viral miRNA. Science 2007, 317, 376–381, doi:10.1126/science.1140956.
[41]
Nachmani, D.; Lankry, D.; Wolf, D.G.; Mandelboim, O. The human cytomegalovirus microRNA miR-UL112 acts synergistically with a cellular microRNA to escape immune elimination. Nat. Immunol. 2010, 11, 806–813.
[42]
Wills, M.R.; Ashiru, O.; Reeves, M.B.; Okecha, G.; Trowsdale, J.; Tomasec, P.; Wilkinson, J.; Sinclair, G.W.; Sissons, J.G. Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. J. Immunol. 2005, 175, 7457–7465.
[43]
Chalupny, N.J.; Rein-Weston, A.; Dosch, S.; Cosman, D. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biophys. Res. Commun. 2006, 346, 175–181, doi:10.1016/j.bbrc.2006.05.092.
[44]
Ashiru, O.; Bennett, N.J.; Boyle, L.H.; Thomas, M.; Trowsdale, J.; Wills, M.R. NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142. J. Virol. 2009, 83, 12345–12354, doi:10.1128/JVI.01175-09.
[45]
Bennett, N.J.; Ashiru, O.; Morgan, F.J.; Pang, Y.; Okecha, G.; Eagle, R.A.; Trowsdale, J.; Sissons, J.G.; Wills, M.R. Intracellular sequestration of the NKG2D ligand ULBP3 by human cytomegalovirus. J. Immunol. 2010, 185, 1093–1102.
[46]
Tomasec, P.; Wang, E.C.; Davison, A.J.; Vojtesek, B.; Armstrong, M.; Griffin, C.; McSharry, B.P.; Morris, R.J.; Llewellyn-Lacey, S.; Rickards, C.; et al. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat. Immunol. 2005, 6, 181–188.
[47]
Prod’homme, V.; Sugrue, D.M.; Stanton, R.J.; Nomoto, A.; Davies, J.; Rickards, C.R.; Cochrane, D.; Moore, M.; Wilkinson, G.W.; Tomasec, P. Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112. J. Gen. Virol. 2010, 91, 2034–2039, doi:10.1099/vir.0.021931-0.
[48]
Smith, W.; Tomasec, P.; Aicheler, R.; Loewendorf, A.; Nemcovicova, I.; Wang, E.C.; Stanton, R.J.; Macauley, M.; Norris, P.; Willen, L.; et al. Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses. Cell Host Microbe 2013, 13, 324–335, doi:10.1016/j.chom.2013.02.003.
[49]
Nemcovicova, I.; Benedict, C.A.; Zajonc, D.M. Structure of human cytomegalovirus UL141 binding to TRAIL-R2 reveals novel, non-canonical death receptor interactions. PLoS Pathog. 2013, 9, e1003224, doi:10.1371/journal.ppat.1003224.
[50]
Vivier, E.; Tomasello, E.; Baratin, M.; Walzer, T.; Ugolini, S. Functions of natural killer cells. Nat. Immunol. 2008, 9, 503–510.
[51]
Jones, T.R.; Wiertz, E.J.; Sun, L.; Fish, K.N.; Nelson, J.A.; Ploegh, H.L. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc. Natl. Acad. Sci. USA 1996, 93, 11327–11333, doi:10.1073/pnas.93.21.11327.
[52]
Wiertz, E.J.; Jones, T.R.; Sun, L.; Bogyo, M.; Geuze, H.J.; Ploegh, H.L. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 1996, 84, 769–779, doi:10.1016/S0092-8674(00)81054-5.
[53]
Jones, T.R.; Hanson, L.K.; Sun, L.; Slater, J.S.; Stenberg, R.M.; Campbell, A.E. Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. J. Virol. 1995, 69, 4830–4841.
[54]
Machold, R.P.; Wiertz, E.J.; Jones, T.R.; Ploegh, H.L. The HCMV gene products US11 and US2 differ in their ability to attack allelic forms of murine major histocompatibility complex (MHC) class I heavy chains. J. Exp. Med. 1997, 185, 363–366, doi:10.1084/jem.185.2.363.
[55]
Ahn, K.; Gruhler, A.; Galocha, B.; Jones, T.R.; Wiertz, E.J.; Ploegh, H.L.; Peterson, P.A.; Yang, Y.; Fruh, K. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 1997, 6, 613–621, doi:10.1016/S1074-7613(00)80349-0.
[56]
Braud, V.; Jones, E.Y.; McMichael, A. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur. J. Immunol. 1997, 27, 1164–1169, doi:10.1002/eji.1830270517.
[57]
Millo, E.; Pietra, G.; Armirotti, A.; Vacca, P.; Mingari, M.C.; Moretta, L.; Damonte, G. Purification and HPLC-MS analysis of a naturally processed HCMV-derived peptide isolated from the HEK-293T/HLA-E+/Ul40+ cell transfectants and presented at the cell surface in the context of HLA-E. J. Immunol. Meth. 2007, 322, 128–136, doi:10.1016/j.jim.2007.01.018.
[58]
Borrego, F.; Ulbrecht, M.; Weiss, E.H.; Coligan, J.E.; Brooks, A.G. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J. Exp. Med. 1998, 187, 813–818, doi:10.1084/jem.187.5.813.
[59]
Braud, V.M.; Allan, D.S.; O’Callaghan, C.A.; Soderstrom, K.; D’Andrea, A.; Ogg, G.S.; Lazetic, S.; Young, N.T.; Bell, J.I.; Phillips, J.H.; et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998, 391, 795–799, doi:10.1038/35869.
[60]
Lee, N.; Llano, M.; Carretero, M.; Ishitani, A.; Navarro, F.; Lopez-Botet, M.; Geraghty, D.E. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl. Acad. Sci. USA 1998, 95, 5199–5204, doi:10.1073/pnas.95.9.5199.
[61]
Kaiser, B.K.; Barahmand-Pour, F.; Paulsene, W.; Medley, S.; Geraghty, D.E.; Strong, R.K. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J. Immunol. 2005, 174, 2878–2884.
[62]
Miller, J.D.; Weber, D.A.; Ibegbu, C.; Pohl, J.; Altman, J.D.; Jensen, P.E. Analysis of HLA-E peptide-binding specificity and contact residues in bound peptide required for recognition by CD94/NKG2. J. Immunol. 2003, 171, 1369–1375.
[63]
Sullivan, L.C.; Clements, C.S.; Beddoe, T.; Johnson, D.; Hoare, H.L.; Lin, J.; Huyton, T.; Hopkins, E.J.; Reid, H.H.; Wilce, M.C.; et al. The heterodimeric assembly of the CD94-NKG2 receptor family and implications for human leukocyte antigen-E recognition. Immunity 2007, 27, 900–911, doi:10.1016/j.immuni.2007.10.013.
[64]
Vales-Gomez, M.; Reyburn, H.T.; Erskine, R.A.; Lopez-Botet, M.; Strominger, J.L. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J. 1999, 18, 4250–4260, doi:10.1093/emboj/18.15.4250.
[65]
Heatley, S.L.; Pietra, G.; Lin, J.; Widjaja, J.M.; Harpur, C.M.; Lester, S.; Rossjohn, J.; Szer, J.; Schwarer, A.; Bradstock, K.; et al. Polymorphism in human cytomegalovirus UL40 impacts on recognition of human leukocyte antigen-E (HLA-E) by natural killer cells. J. Biol. Chem. 2013, 288, 8679–8690, doi:10.1074/jbc.M112.409672.
[66]
Llano, M.; Lee, N.; Navarro, F.; Garcia, P.; Albar, J.P.; Geraghty, D.E.; Lopez-Botet, M. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur. J. Immunol. 1998, 28, 2854–2863, doi:10.1002/(SICI)1521-4141(199809)28:09<2854::AID-IMMU2854>3.0.CO;2-W.
[67]
Bjorkstrom, N.K.; Lindgren, T.; Stoltz, M.; Fauriat, C.; Braun, M.; Evander, M.; Michaelsson, J.; Malmberg, K.J.; Klingstrom, J.; Ahlm, C.; et al. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J. Exp. Med. 2011, 208, 13–21, doi:10.1084/jem.20100762.
[68]
Petitdemange, C.; Becquart, P.; Wauquier, N.; Beziat, V.; Debre, P.; Leroy, E.M.; Vieillard, V. Unconventional repertoire profile is imprinted during acute chikungunya infection for natural killer cells polarization toward cytotoxicity. PLoS Pathog. 2011, 7, e1002268, doi:10.1371/journal.ppat.1002268.
[69]
Brunetta, E.; Fogli, M.; Varchetta, S.; Bozzo, L.; Hudspeth, K.L.; Marcenaro, E.; Moretta, A.; Mavilio, D. Chronic HIV-1 viremia reverses NKG2A/NKG2C ratio on natural killer cells in patients with human cytomegalovirus co-infection. AIDS 2010, 24, 27–34, doi:10.1097/QAD.0b013e3283328d1f.
[70]
Beziat, V.; Dalgard, O.; Asselah, T.; Halfon, P.; Bedossa, P.; Boudifa, A.; Hervier, B.; Theodorou, I.; Martinot, M.; Debre, P.; et al. CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur. J. Immunol. 2012, 42, 447–457, doi:10.1002/eji.201141826.
[71]
Monsivais-Urenda, A.; Noyola-Cherpitel, D.; Hernandez-Salinas, A.; Garcia-Sepulveda, C.; Romo, N.; Baranda, L.; Lopez-Botet, M.; Gonzalez-Amaro, R. Influence of human cytomegalovirus infection on the NK cell receptor repertoire in children. Eur. J. Immunol. 2010, 40, 1418–1427, doi:10.1002/eji.200939898.
[72]
Petersen, L.; Roug, A.S.; Skovbo, A.; Thysen, A.H.; Eskelund, C.W.; Hokland, M.E. The CD94/NKG2C-expressing NK cell subset is augmented in chronic lymphocytic leukemia patients with positive human cytomegalovirus serostatus. Viral. Immunol. 2009, 22, 333–337, doi:10.1089/vim.2009.0032.
[73]
Guma, M.; Cabrera, C.; Erkizia, I.; Bofill, M.; Clotet, B.; Ruiz, L.; Lopez-Botet, M. Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J. Infect. Dis. 2006, 194, 38–41, doi:10.1086/504719.
[74]
Noyola, D.E.; Fortuny, C.; Muntasell, A.; Noguera-Julian, A.; Munoz-Almagro, C.; Alarcon, A.; Juncosa, T.; Moraru, M.; Vilches, C.; Lopez-Botet, M. Influence of congenital human cytomegalovirus infection and the NKG2C genotype on NK-cell subset distribution in children. Eur. J. Immunol. 2012, 42, 3256–3266, doi:10.1002/eji.201242752.
[75]
Foley, B.; Cooley, S.; Verneris, M.R.; Pitt, M.; Curtsinger, J.; Luo, X.; Lopez-Verges, S.; Lanier, L.L.; Weisdorf, D.; Miller, J.S. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012, 119, 2665–2674, doi:10.1182/blood-2011-10-386995.
[76]
Chiesa, D.M.; Falco, M.; Podesta, M.; Locatelli, F.; Moretta, L.; Frassoni, F.; Moretta, A. Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: A role for human cytomegalovirus? Blood 2012, 119, 399–410.
[77]
Lopez-Verges, S.; Milush, J.M.; Schwartz, B.S.; Pando, M.J.; Jarjoura, J.; York, V.A.; Houchins, J.P.; Miller, S.; Kang, S.M.; Norris, P.J.; et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl. Acad. Sci. USA 2011, 108, 14725–14732.
[78]
Charoudeh, H.N.; Terszowski, G.; Czaja, K.; Gonzalez, A.; Schmitter, K.; Stern, M. Modulation of the natural killer cell KIR repertoire by cytomegalovirus infection. Eur. J. Immunol. 2013, 43, 480–487, doi:10.1002/eji.201242389.
[79]
Beziat, V.; Liu, L.L.; Malmberg, J.A.; Ivarsson, M.A.; Sohlberg, E.; Bjorklund, A.T.; Retiere, C.; Sverremark-Ekstrom, E.; Traherne, J.; Ljungman, P.; et al. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood 2013, 121, 2678–2688, doi:10.1182/blood-2012-10-459545.
[80]
Djaoud, Z.; David, G.; Bressollette, C.; Willem, C.; Rettman, P.; Gagne, K.; Legrand, N.; Mehlal, S.; Cesbron, A.; Imbert-Marcille, B.M.; et al. Amplified NKG2C+ NK cells in cytomegalovirus (CMV) infection preferentially express killer cell Ig-like receptor 2DL: functional impact in controlling CMV-infected dendritic cells. J. Immunol. 2013, 191, 2708–2716, doi:10.4049/jimmunol.1301138.
[81]
Moraru, M.; Cisneros, E.; Gomez-Lozano, N.; de Pablo, R.; Portero, F.; Canizares, M.; Vaquero, M.; Roustan, G.; Millan, I.; Lopez-Botet, M.; et al. Host genetic factors in susceptibility to herpes simplex type 1 virus infection: contribution of polymorphic genes at the interface of innate and adaptive immunity. J. Immunol. 2012, 188, 4412–4420, doi:10.4049/jimmunol.1103434.
[82]
Muntasell, A.; Vilches, C.; Angulo, A.; Lopez-Botet, M. Adaptive reconfiguration of the human NK-cell compartment in response to cytomegalovirus: a different perspective of the host-pathogen interaction. Eur. J. Immunol. 2013, 43, 1133–1141, doi:10.1002/eji.201243117.
[83]
Hikami, K.; Tsuchiya, N.; Yabe, T.; Tokunaga, K. Variations of human killer cell lectin-like receptors: Common occurrence of NKG2-C deletion in the general population. Genes Immun. 2003, 4, 160–167, doi:10.1038/sj.gene.6363940.
[84]
Miyashita, R.; Tsuchiya, N.; Hikami, K.; Kuroki, K.; Fukazawa, T.; Bijl, M.; Kallenberg, C.G.; Hashimoto, H.; Yabe, T.; Tokunaga, K. Molecular genetic analyses of human NKG2C (KLRC2) gene deletion. Int. Immunol. 2004, 16, 163–168, doi:10.1093/intimm/dxh013.
[85]
Moraru, M.; Canizares, M.; Muntasell, A.; de Pablo, R.; Lopez-Botet, M.; Vilches, C. Assessment of copy-number variation in the NKG2C receptor gene in a single-tube and characterization of a reference cell panel, using standard polymerase chain reaction. Tissue Antigens 2012, 80, 184–187, doi:10.1111/j.1399-0039.2012.01911.x.
[86]
Munoz-Cobo, B.; Solano, C.; Benet, I.; Costa, E.; Remigia, M.J.; de la Camara, R.; Nieto, J.; Lopez, J.; Amat, P.; Garcia-Noblejas, A.; et al. Functional profile of cytomegalovirus (CMV)-specific CD8+ T cells and kinetics of NKG2C+ NK cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients. J. Med. Virol. 2012, 84, 259–267, doi:10.1002/jmv.22254.
[87]
Wu, Z.; Sinzger, C.; Frascaroli, G.; Reichel, J.; Bayer, C.; Wang, L.; Schirmbeck, R.; Mertens, T. Human cytomegalovirus-induced NKG2C(hi) CD57(hi) natural killer cells are effectors dependent on humoral antiviral immunity. J. Virol. 2013, 87, 7717–7725, doi:10.1128/JVI.01096-13.
[88]
Guma, M.; Budt, M.; Saez, A.; Brckalo, T.; Hengel, H.; Angulo, A.; Lopez-Botet, M. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 2006, 107, 3624–3631, doi:10.1182/blood-2005-09-3682.
[89]
Beziat, V.; Hervier, B.; Achour, A.; Boutolleau, D.; Marfain-Koka, A.; Vieillard, V. Human NKG2A overrides NKG2C effector functions to prevent autoreactivity of NK cells. Blood 2011, 117, 4394–4396, doi:10.1182/blood-2010-11-319194.
[90]
Foley, B.; Cooley, S.; Verneris, M.R.; Curtsinger, J.; Luo, X.; Waller, E.K.; Anasetti, C.; Weisdorf, D.; Miller, J.S. Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J. Immunol. 2012, 189, 5082–5088, doi:10.4049/jimmunol.1201964.
[91]
Daeron, M. Fc receptor biology. Annu. Rev. Immunol. 1997, 15, 203–234, doi:10.1146/annurev.immunol.15.1.203.
[92]
Ravetch, J.V.; Perussia, B. Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J. Exp. Med. 1989, 170, 481–497, doi:10.1084/jem.170.2.481.
[93]
Wirthmueller, U.; Kurosaki, T.; Murakami, M.S.; Ravetch, J.V. Signal transduction by Fc gamma RIII (CD16) is mediated through the gamma chain. J. Exp. Med. 1992, 175, 1381–1390, doi:10.1084/jem.175.5.1381.
Hazenbos, W.L.; Gessner, J.E.; Hofhuis, F.M.; Kuipers, H.; Meyer, D.; Heijnen, I.A.; Schmidt, R.E.; Sandor, M.; Capel, P.J.; Daeron, M.; et al. Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity 1996, 5, 181–188, doi:10.1016/S1074-7613(00)80494-X.
[96]
Hwang, I.; Zhang, T.; Scott, J.M.; Kim, A.R.; Lee, T.; Kakarla, T.; Kim, A.; Sunwoo, J.B.; Kim, S. Identification of human NK cells that are deficient for signaling adaptor FcRgamma and specialized for antibody-dependent immune functions. Int. Immunol. 2012, 24, 793–802, doi:10.1093/intimm/dxs080.
[97]
Zhang, T.; Scott, J.M.; Hwang, I.; Kim, S. Cutting edge: antibody-dependent memory-like NK cells distinguished by FcRgamma deficiency. J. Immunol. 2013, 190, 1402–1406, doi:10.4049/jimmunol.1203034.
[98]
Mandelboim, O.; Lieberman, N.; Lev, M.; Paul, L.; Arnon, T.I.; Bushkin, Y.; Davis, D.M.; Strominger, J.L.; Yewdell, J.W.; Porgador, A. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001, 409, 1055–1060, doi:10.1038/35059110.
[99]
Hecht, M.L.; Rosental, B.; Horlacher, T.; Hershkovitz, O.; de Paz, J.L.; Noti, C.; Schauer, S.; Porgador, A.; Seeberger, P.H. Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences. J. Proteome Res. 2009, 8, 712–720, doi:10.1021/pr800747c.
[100]
Romo, N.; Magri, G.; Muntasell, A.; Heredia, G.; Baia, D.; Angulo, A.; Guma, M.; Lopez-Botet, M. Natural killer cell-mediated response to human cytomegalovirus-infected macrophages is modulated by their functional polarization. J. Leukoc. Biol. 2011, 90, 717–726, doi:10.1189/jlb.0311171.
[101]
Magri, G.; Muntasell, A.; Romo, N.; Saez-Borderias, A.; Pende, D.; Geraghty, D.E.; Hengel, H.; Angulo, A.; Moretta, A.; Lopez-Botet, M. NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies. Blood 2011, 117, 848–856, doi:10.1182/blood-2010-08-301374.
[102]
Pessino, A.; Sivori, S.; Bottino, C.; Malaspina, A.; Morelli, L.; Moretta, L.; Biassoni, R.; Moretta, A. Molecular cloning of NKp46: A novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J. Exp. Med. 1998, 188, 953–960.
[103]
Moretta, A.; Biassoni, R.; Bottino, C.; Mingari, M.C.; Moretta, L. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol. Today 2000, 21, 228–234, doi:10.1016/S0167-5699(00)01596-6.
[104]
Nigro, G.; Adler, S.P.; Torre, L.R.; Best, A.M. Passive immunization during pregnancy for congenital cytomegalovirus infection. N. Engl. J. Med. 2005, 353, 1350–1362, doi:10.1056/NEJMoa043337.
Snydman, D.R.; Werner, B.G.; Heinze-Lacey, B.; Berardi, V.P.; Tilney, N.L.; Kirkman, R.L.; Milford, E.L.; Cho, S.I.; Bush, H.L.J.; Levey, A.S.; et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N. Engl. J. Med. 1987, 317, 1049–1054, doi:10.1056/NEJM198710223171703.
[107]
Metselaar, H.J.; Rothbarth, P.H.; Brouwer, R.M.; Wenting, G.J.; Jeekel, J.; Weimar, W. Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated for rejection. Transplantation 1989, 48, 264–266, doi:10.1097/00007890-198908000-00016.
[108]
Alexander, B.T.; Hladnik, L.M.; Augustin, K.M.; Casabar, E.; McKinnon, P.S.; Reichley, R.M.; Ritchie, D.J.; Westervelt, P.; Dubberke, E.R. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy 2010, 30, 554–561, doi:10.1592/phco.30.6.554.
[109]
Tsevat, J.; Snydman, D.R.; Pauker, S.G.; Durand-Zaleski, I.; Werner, B.G.; Levey, A.S. Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysis. Transplantation 1991, 52, 259–265.
[110]
Raanani, P.; Gafter-Gvili, A.; Paul, M.; Ben-Bassat, I.; Leibovici, L.; Shpilberg, O. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst. Rev. 2008, 4, CD006501.
[111]
Britt, W.J.; Vugler, L.; Butfiloski, E.J.; Stephens, E.B. Cell surface expression of human cytomegalovirus (HCMV) gp55–116 (gB): Use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J. Virol. 1990, 64, 1079–1085.
[112]
Adler, B.; Scrivano, L.; Ruzcics, Z.; Rupp, B.; Sinzger, C.; Koszinowski, U. Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J. Gen. Virol. 2006, 87, 2451–2460, doi:10.1099/vir.0.81921-0.
[113]
Revello, M.G.; Gerna, G. Human cytomegalovirus tropism for endothelial/epithelial cells: Scientific background and clinical implications. Rev. Med. Virol. 2010, 20, 136–155, doi:10.1002/rmv.645.
[114]
Lilleri, D.; Kabanova, A.; Revello, M.G.; Percivalle, E.; Sarasini, A.; Genini, E.; Sallusto, F.; Lanzavecchia, A.; Corti, D.; Gerna, G. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128–130–131 complex during primary infection. PLoS One 2013, 8, e59863.
[115]
Macagno, A.; Bernasconi, N.L.; Vanzetta, F.; Dander, E.; Sarasini, A.; Revello, M.G.; Gerna, G.; Sallusto, F.; Lanzavecchia, A. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128–131A complex. J. Virol. 2010, 84, 1005–1013, doi:10.1128/JVI.01809-09.
[116]
Hahn, G.; Revello, M.G.; Patrone, M.; Percivalle, E.; Campanini, G.; Sarasini, A.; Wagner, M.; Gallina, A.; Milanesi, G.; Koszinowski, U.; et al. Human cytomegalovirus UL131–128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J. Virol. 2004, 78, 10023–10033, doi:10.1128/JVI.78.18.10023-10033.2004.
[117]
Ryckman, B.J.; Rainish, B.L.; Chase, M.C.; Borton, J.A.; Nelson, J.A.; Jarvis, M.A.; Johnson, D.C. Characterization of the human cytomegalovirus gH/gL/UL128–131 complex that mediates entry into epithelial and endothelial cells. J. Virol. 2008, 82, 60–70, doi:10.1128/JVI.01910-07.
[118]
Wang, D.; Shenk, T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl. Acad. Sci. USA 2005, 102, 18153–18158, doi:10.1073/pnas.0509201102.
[119]
Wang, D.; Shenk, T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J. Virol. 2005, 79, 10330–10338, doi:10.1128/JVI.79.16.10330-10338.2005.
[120]
Genini, E.; Percivalle, E.; Sarasini, A.; Revello, M.G.; Baldanti, F.; Gerna, G. Serum antibody response to the gH/gL/pUL128–131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. J. Clin. Virol. 2011, 52, 113–118, doi:10.1016/j.jcv.2011.06.018.
[121]
Fouts, A.E.; Chan, P.; Stephan, J.P.; Vandlen, R.; Feierbach, B. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J. Virol. 2012, 86, 7444–7447, doi:10.1128/JVI.00467-12.
[122]
Plotkin, S.A.; Starr, S.E.; Friedman, H.M.; Brayman, K.; Harris, S.; Jackson, S.; Tustin, N.B.; Grossman, R.; Dafoe, D.; Barker, C. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann. Intern. Med. 1991, 114, 525–531, doi:10.7326/0003-4819-114-7-525.
Adler, S.P.; Starr, S.E.; Plotkin, S.A.; Hempfling, S.H.; Buis, J.; Manning, M.L.; Best, A.M. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J. Infect. Dis. 1995, 171, 26–32, doi:10.1093/infdis/171.1.26.
[125]
Sabbaj, S.; Pass, R.F.; Goepfert, P.A.; Pichon, S. Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J. Infect. Dis. 2011, 203, 1534–1541, doi:10.1093/infdis/jir138.
[126]
Pass, R.F.; Zhang, C.; Evans, A.; Simpson, T.; Andrews, W.; Huang, M.L.; Corey, L.; Hill, J.; Davis, E.; Flanigan, C.; et al. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 2009, 360, 1191–1199, doi:10.1056/NEJMoa0804749.
[127]
Pass, R.F.; Duliege, A.M.; Boppana, S.; Sekulovich, R.; Percell, S.; Britt, W.; Burke, R.L. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J. Infect. Dis. 1999, 180, 970–975, doi:10.1086/315022.
[128]
Griffiths, P.D.; Stanton, A.; McCarrell, E.; Smith, C.; Osman, M.; Harber, M.; Davenport, A.; Jones, G.; Wheeler, D.C.; O’Beirne, J.; et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377, 1256–1263, doi:10.1016/S0140-6736(11)60136-0.
[129]
Nokta, M.; Tolpin, M.D.; Nadler, P.I.; Pollard, R.B. Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): Enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication. Antivir. Res. 1994, 24, 17–26, doi:10.1016/0166-3542(94)90048-5.
[130]
Manley, K.; Anderson, J.; Yang, F.; Szustakowski, J.; Oakeley, E.J.; Compton, T.; Feire, A.L. Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions. Cell Host Microbe 2011, 10, 197–209, doi:10.1016/j.chom.2011.07.010.
[131]
Jabs, D.A.; Gilpin, A.M.; Min, Y.I.; Erice, A.; Kempen, J.H.; Quinn, T.C. HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial. AIDS 2002, 16, 877–887, doi:10.1097/00002030-200204120-00007.
[132]
Boeckh, M.; Bowden, R.A.; Storer, B.; Chao, N.J.; Spielberger, R.; Tierney, D.K.; Gallez-Hawkins, G.; Cunningham, T.; Blume, K.G.; Levitt, D.; et al. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2001, 7, 343–351, doi:10.1016/S1083-8791(01)80005-7.
[133]
Jegaskanda, S.; Job, E.R.; Kramski, M.; Laurie, K.; Isitman, G.; de Rose, R.; Winnall, W.R.; Stratov, I.; Brooks, A.G.; Reading, P.C.; et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J. Immunol. 2013, 190, 1837–1848, doi:10.4049/jimmunol.1201574.
[134]
Jia, M.; Li, D.; He, X.; Zhao, Y.; Peng, H.; Ma, P.; Hong, K.; Liang, H.; Shao, Y. Impaired natural killer cell-induced antibody-dependent cell-mediated cytotoxicity is associated with human immunodeficiency virus-1 disease progression. Clin. Exp. Immunol. 2013, 171, 107–116.
[135]
Hansen, S.G.; Powers, C.J.; Richards, R.; Ventura, A.B.; Ford, J.C.; Siess, D.; Axthelm, M.K.; Nelson, J.A.; Jarvis, M.A.; Picker, L.J.; et al. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 2010, 328, 102–106, doi:10.1126/science.1185350.
